

9 December 2025

Pre-quotations Disclosure

Moonlight Resources Ltd (**Company**) makes the following disclosures in accordance with ASX's listing conditions.

Capitalised terms not otherwise defined have the meaning given in the Company's Replacement Prospectus dated 19 November 2025 (**Prospectus**).

1 Restricted Securities

The following table provides the number of securities subject to ASX restrictions and the restriction period applied to those securities:

Security	Number of securities	Restriction period
Pre-IPO Shares	22,025,492	24 months from the date the Company's Shares are quoted on the official list of the ASX
Diatreme Shares	16,250,000	
Options	26,000,000	
IPO Performance Rights	7,858,383	
Pre-IPO Shares	2,650,001	12 months from the date of issue

2 Confirmation of no impediments

The Company confirms there are no legal, regulatory, statutory or contractual impediments to the Company entering and carrying out exploration activities on the Clermont Project, MacDonnell Ranges Project, Fox Hill Project, Moonlight Project and Drysdale Uranium Project such that the Company will be able to spend its cash in accordance with its commitments for the purposes of Listing Rule 1.3.2(b).

3 Completion of Offers and issuance of Securities

The Company is pleased to announce it raised \$10 million (before costs) (**Offer Amount**) under the Offer. The Company has received the Offer Amount in cleared funds.

The Company confirms that it has closed the Offer under the Prospectus and completed the issue of:

- 50,000,000 Shares;
- 500,000 Broker Options to Leeuwin Wealth (or its nominees);
- 500,000 Broker Options to Richlink Capital;
- 25,000,013 Attaching Options;

- 25,000,000 Sub-underwriting Options, and
- 16,250,000 Diatreme Shares.

In addition, the Company approved the issuance of 7,858,383 IPO Performance Rights on 27 October 2025, under the terms disclosed in the Prospectus. The IPO Performance Rights were issued on 4 December 2025.

4 Rounding-up of Attaching Options

Under the terms of the Offer, applicants were entitled to receive one Attaching Options for every two Shares subscribed, for a total of 25,000,000 Attaching Options.

In the process of completing the allocation of the Shares, 26 applicants applied for a number of Shares that would grant them a fractional Attaching Option. The Company, in consultation with the Underwriter, rounded up such fractional Attaching Options. The rounding-up determined the issuance of additional 13 Attaching Options. The Company decided to proceed with the fractional rounding-up due to the immateriality of the number of additional Attaching Options issued and to align with market practice.

5 Company Capital Structure

As of the date of this disclosure, the capital structure of the Company is set out below:

Security Type	Number of Issued securities
Ordinary shares on issue after completion of the Offer	96,933,835
Total options on issue after completion of the Offer	51,000,013
Performance rights on issue after completion of the offer	7,858,383

6 Waivers

ASX has granted the Company the waiver in Annexure A.

7 Completion of the acquisition of the shares in Chalcophile Resources Pty Ltd and PGE Minerals Pty Ltd

On 5 December 2025, all the conditions precedent to completion of the acquisition of the shares in Chalcophile Resources Pty Ltd and PGE Minerals Pty Ltd were satisfied. As a result, the Company completed the agreement with Lucky Break Operations Pty Ltd, Regional Exploration Management Pty Ltd and Diatreme Resourced Limited, dated 28 October 2025. According to the terms of such agreement, the Company paid \$250,000 cash to Diatreme, as reimbursement for exploration activities undertaken at the Clermont Project, and issued the Diatreme Shares.

The terms of the Sale Agreement have been disclosed in the Prospectus.

Authorised for release by the Board.

Greg Starr
Managing Director
Moonlight Resources Ltd

Annexure A – Waiver

Moonlight Resources Ltd (ASX:ML8, **Moonlight**) provides the following information in respect of its admission to the Official List of the Australian Securities Exchange (ASX) and quotation of its ordinary shares.

Unless otherwise defined, capitalised terms in this announcement have the meaning given to them in the replacement prospectus issued by Moonlight and lodged with the Australian Securities and Investments Commission on 19 November 2025 (**Replacement Prospectus**).

ASX Waiver

As part of its listing process, Moonlight requested a waiver from Listing Rule 1.1 (Condition 12) (**Waiver**) in relation to the IPO Performance Rights. Under Listing Rule 1.1 (Condition 12), if an entity seeking admission to the official list has performance rights on issue, the exercise price for each performance right must be at least 20 cents in cash. Moonlight requested the Waiver because the IPO Performance Rights have a nil exercise price. A waiver from Listing Rule (Condition 12) can be granted on condition that the full terms and conditions of the securities the subject of the waiver application are clearly disclosed in the issuer's initial public offering prospectus.

Moonlight issued 7,858,383 IPO Performance Rights. The number of IPO Performance Rights represents 8.1% of the total ordinary shares on issue (96,933,825 ordinary shares) following the completion of the Offer. The terms of the IPO Performance Rights have been fully disclosed in the Replacement Prospectus.

The terms of the milestones of the IPO Performance Rights (and the split of vesting of the performance rights across those milestones) were determined by the Board of Moonlight in consultation with, and with the encouragement of, the Joint Lead Managers to the Offer as an alternative to any employee option plan. The IPO Performance Rights have been designed to align directors' and management's interests and the remuneration for their performance with creation of shareholder value, in the context of the development stage of Moonlight's projects and its growth strategy. Thus, the Board of Moonlight determined that a nil exercise price for the IPO Performance Rights, together with the challenging milestone requirements, would link the directors' and management's interests and the remuneration for their performance with the creation of shareholder value. The number and terms of the performance rights were considered appropriate based on the development stage of Moonlight's projects. As a result, Moonlight requested the Waiver.

On 24 November 2025, ASX granted Moonlight the Waiver.